Cannabinoids Data Research and Development Safety 
Cannabis Law Report
NOVEMBER 2, 2021
Earlier this month, the FDA released a seven-page plan to accelerate its research into the safety of cannabis-derived products. Piloting market surveillance tools to monitor unapproved cannabis-derived products and “identify potential safety issues before the issues become mainstream.”
Cannabis Law Report
DECEMBER 7, 2021
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JULY 1, 2022
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
Cannabis Law Report
JULY 8, 2021
Seeks To Identify Novel Cannabinoids For Therapeutic Use. The Company expects to finalize the agreement with the research institute and commence studies by Fall 2021. The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. CHARLOTTE, N.C.–(BUSINESS
Cannabis Law Report
MAY 18, 2022
Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.
Cannabis Law Report
MAY 18, 2022
NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.
Veriheal
APRIL 11, 2022
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
Expert insights. Personalized for you.
52 
Let's personalize your content